These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 28103901)

  • 21. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.
    Chen C; Soto G; Dumrongprechachan V; Bannon N; Kang S; Kozorovitskiy Y; Parisiadou L
    Elife; 2020 Oct; 9():. PubMed ID: 33006315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
    Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
    Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
    Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S
    J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The LRRK2 signalling system.
    Price A; Manzoni C; Cookson MR; Lewis PA
    Cell Tissue Res; 2018 Jul; 373(1):39-50. PubMed ID: 29308544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
    West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
    Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.
    Heckman MG; Elbaz A; Soto-Ortolaza AI; Serie DJ; Aasly JO; Annesi G; Auburger G; Bacon JA; Boczarska-Jedynak M; Bozi M; Brighina L; Chartier-Harlin MC; Dardiotis E; Destée A; Ferrarese C; Ferraris A; Fiske B; Gispert S; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lin CH; Lohmann K; Loriot MA; Lynch T; Mellick GD; Mutez E; Opala G; Park SS; Petrucci S; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Tomiyama H; Uitti RJ; Valente EM; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Xiromerisiou G; Maraganore DM; Farrer MJ; Ross OA;
    Neurobiol Aging; 2014 Jan; 35(1):266.e5-14. PubMed ID: 23962496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
    Ito G; Utsunomiya-Tate N
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.
    Coku I; Mutez E; Eddarkaoui S; Carrier S; Marchand A; Deldycke C; Goveas L; Baille G; Tir M; Magnez R; Thuru X; Vermeersch G; Vandenberghe W; Buée L; Defebvre L; Sablonnière B; Chartier-Harlin MC; Taymans JM; Huin V
    Mov Disord; 2022 Aug; 37(8):1761-1767. PubMed ID: 35708213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRRK2 links genetic and sporadic Parkinson's disease.
    Kluss JH; Mamais A; Cookson MR
    Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LRRK2 Phosphorylation: Behind the Scenes.
    De Wit T; Baekelandt V; Lobbestael E
    Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
    Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
    Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRRK2 and mitochondria: Recent advances and current views.
    Singh A; Zhi L; Zhang H
    Brain Res; 2019 Jan; 1702():96-104. PubMed ID: 29894679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.
    Azkona G; López de Maturana R; Del Rio P; Sousa A; Vazquez N; Zubiarrain A; Jimenez-Blasco D; Bolaños JP; Morales B; Auburger G; Arbelo JM; Sánchez-Pernaute R
    Mol Neurobiol; 2018 Jan; 55(1):506-516. PubMed ID: 27975167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
    Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
    Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The APP intracellular domain promotes
    Zhang ZW; Tu H; Jiang M; Vanan S; Chia SY; Jang SE; Saw WT; Ong ZW; Ma DR; Zhou ZD; Xu J; Guo KH; Yu WP; Ling SC; Margolin RA; Chain DG; Zeng L; Tan EK
    Sci Signal; 2022 Aug; 15(748):eabk3411. PubMed ID: 35998231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
    Ho DH; Seol W; Son I
    Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
    Lai D; Alipanahi B; Fontanillas P; Schwantes-An TH; Aasly J; Alcalay RN; Beecham GW; Berg D; Bressman S; Brice A; Brockman K; Clark L; Cookson M; Das S; Van Deerlin V; Follett J; Farrer MJ; Trinh J; Gasser T; Goldwurm S; Gustavsson E; Klein C; Lang AE; Langston JW; Latourelle J; Lynch T; Marder K; Marras C; Martin ER; McLean CY; Mejia-Santana H; Molho E; Myers RH; Nuytemans K; Ozelius L; Payami H; Raymond D; Rogaeva E; Rogers MP; Ross OA; Samii A; Saunders-Pullman R; Schüle B; Schulte C; Scott WK; Tanner C; Tolosa E; Tomkins JE; Vilas D; Trojanowski JQ; ; Uitti R; Vance JM; Visanji NP; Wszolek ZK; Zabetian CP; Mirelman A; Giladi N; Orr Urtreger A; Cannon P; Fiske B; Foroud T
    Ann Neurol; 2021 Jul; 90(1):76-88. PubMed ID: 33938021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.